VALBY, Denmark and AMSTERDAM, Netherlands, June 3, 2026
Lundbeck and Cradle have announced a strategic partnership aimed at transforming the discovery and optimization of next-generation biologics for neurological and psychiatric disorders through advanced artificial intelligence-driven protein engineering. The collaboration combines Lundbeck’s extensive expertise in neuroscience and brain health with Cradle’s cutting-edge generative AI platform to accelerate the development of innovative therapeutics targeting central nervous system (CNS) diseases. As the global burden of brain disorders continues to rise, affecting more than half of the world’s population, the partnership seeks to significantly reduce drug discovery timelines, improve biologic candidate quality, and increase the likelihood of clinical success. The initiative represents another major step in Lundbeck’s strategy to become a fully integrated AI-enabled biopharmaceutical innovator, leveraging advanced computational technologies to deliver transformative treatments for patients with limited therapeutic options.
AI-Powered Platform to Advance Biotherapeutic Innovation
The collaboration will initially focus on two antibody-based programs targeting CNS diseases, utilizing Cradle’s enterprise-grade AI platform to optimize protein design and biologic engineering. The platform enables researchers to create, evaluate, and refine therapeutic proteins through a continuous learning process in which laboratory-generated experimental data are repeatedly fed back into AI models. This closed-loop system improves predictive accuracy with each iteration and significantly reduces the number of laboratory experiments required to identify high-performing drug candidates.
By combining computational intelligence with real-world biological validation, Lundbeck aims to accelerate the transition from discovery-stage concepts to clinically viable biologics. Scientists from Lundbeck’s protein engineering and computational biology teams will use the technology to engineer antibody candidates with enhanced efficacy, stability, manufacturability, and therapeutic potential. The approach is expected to streamline development workflows while increasing the probability of identifying successful treatments for complex neurological diseases.
Accelerating Drug Discovery Through Generative AI
Advertisement
The partnership marks Lundbeck’s first fully integrated end-to-end AI-guided protein engineering workflow, a milestone that reflects the growing adoption of artificial intelligence across pharmaceutical research and development. According to the companies, AI-powered design cycles have demonstrated the potential to shorten development timelines dramatically while improving candidate quality. Lundbeck estimates that AI-enabled initiatives across its organization are already contributing more than 12,000 hours of productivity gains every week, while scientific analyses that previously required months can now be completed in less than 24 hours.
Furthermore, the application of advanced AI technologies has expanded the searchable scientific landscape by approximately 50,000-fold, enabling researchers to explore a vastly larger range of therapeutic possibilities than traditional methods allow. By reducing reliance on repetitive laboratory experimentation and improving predictive capabilities, AI-driven drug discovery is increasingly becoming a critical tool for accelerating innovation in biologics development and addressing complex disease biology.
Strengthening Lundbeck’s Vision for AI-Driven Neuroscience Research
The collaboration with Cradle builds upon Lundbeck’s broader strategy of integrating artificial intelligence throughout its research ecosystem. Recently, the company announced a separate partnership with the Danish Centre for AI Innovation, providing access to Denmark’s powerful Gefion AI supercomputer for large-scale scientific modeling and computational drug discovery. Together, these initiatives create a comprehensive AI-enabled infrastructure that spans target identification, molecular design, protein optimization, and translational research.
The combined capabilities are expected to strengthen Lundbeck’s neuroscience pipeline and accelerate the discovery of treatments for neurological and psychiatric disorders that currently lack effective therapeutic options. As the pharmaceutical industry increasingly embraces machine learning and generative AI technologies, the Lundbeck-Cradle alliance highlights how digital innovation is reshaping biopharmaceutical research and creating new opportunities to deliver precision-designed therapies faster, more efficiently, and with greater potential clinical impact.
The partnership underscores the growing convergence of artificial intelligence, biologics engineering, and neuroscience research, positioning Lundbeck among the leaders driving the next generation of AI-powered drug discovery and development.
Source: Lundbeck, Cradle press release
